These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 34333237)
1. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases. Bolhuis K; van 't Erve I; Mijnals C; Delis-Van Diemen PM; Huiskens J; Komurcu A; Lopez-Yurda M; van den Broek D; Swijnenburg RJ; Meijer GA; Punt CJA; Fijneman RJA EBioMedicine; 2021 Aug; 70():103498. PubMed ID: 34333237 [TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694 [TBL] [Abstract][Full Text] [Related]
3. Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases. Liu M; Bao Q; Zhao T; Huang L; Zhang D; Wang Y; Yan X; Wang H; Jin K; Liu W; Wang K; Xing B Hepatol Int; 2024 Jun; 18(3):1029-1039. PubMed ID: 38427145 [TBL] [Abstract][Full Text] [Related]
4. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868 [No Abstract] [Full Text] [Related]
6. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study. Li Y; Xu J; Hu X; Chen Y; Liu F; Chen Y; Ma X; Dong Q; Sun L; Mo S; Zhang L; He X; Tong S; Wu H; Li W; Cai S; Zhu S; Pan Q; Peng J Int J Surg; 2024 May; 110(5):2776-2787. PubMed ID: 38445460 [TBL] [Abstract][Full Text] [Related]
7. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA. Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397 [TBL] [Abstract][Full Text] [Related]
8. Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study. Liu W; Jin KM; Zhang MH; Bao Q; Liu M; Xu D; Wang K; Xing BC Ann Surg Oncol; 2023 Aug; 30(8):4916-4926. PubMed ID: 37219651 [TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases. Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972 [TBL] [Abstract][Full Text] [Related]
10. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540 [TBL] [Abstract][Full Text] [Related]
11. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer. Hassan F; Wang JH; O'Leary DP; Corrigan M; Redmond HP Surg Oncol; 2024 Jun; 54():102060. PubMed ID: 38603927 [TBL] [Abstract][Full Text] [Related]
12. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. Bansal VV; Belmont E; Godley F; Dhiman A; Witmer HD; Li S; Liao A; Eng OS; Turaga KK; Shergill A J Am Coll Surg; 2024 Jun; 238(6):1013-1020. PubMed ID: 38299640 [TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746 [TBL] [Abstract][Full Text] [Related]
14. D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer. Watanabe A; Araki K; Harimoto N; Kubo N; Igarashi T; Ishii N; Yamanaka T; Hagiwara K; Kuwano H; Shirabe K Int J Clin Oncol; 2018 Aug; 23(4):689-697. PubMed ID: 29574651 [TBL] [Abstract][Full Text] [Related]
15. Tumor Mutational Burden From Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection: An Emerging Biomarker for Surveillance. Wehrle CJ; Hong H; Kamath S; Schlegel A; Fujiki M; Hashimoto K; Kwon DCH; Miller C; Walsh RM; Aucejo F Ann Surg; 2024 Sep; 280(3):504-513. PubMed ID: 38860385 [TBL] [Abstract][Full Text] [Related]
16. Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Wullaert L; van Rees JM; Martens JWM; Verheul HMW; Grünhagen DJ; Wilting SM; Verhoef C Cells; 2023 Oct; 12(21):. PubMed ID: 37947598 [TBL] [Abstract][Full Text] [Related]
17. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Newhook TE; Overman MJ; Chun YS; Dasari A; Tzeng CD; Cao HST; Raymond V; Parseghian C; Johnson B; Nishioka Y; Kawaguchi Y; Uppal A; Vreeland TJ; Jaimovich A; Arvide EM; Cristo JV; Wei SH; Raghav KP; Morris VK; Lee JE; Kopetz S; Vauthey JN Ann Surg; 2023 May; 277(5):813-820. PubMed ID: 35797554 [TBL] [Abstract][Full Text] [Related]
18. Impact of Metformin Use on Survival in Patients Undergoing Liver Resection for Colorectal Cancer Metastases. Kaltenmeier C; Morocco B; Yazdani H; Reitz K; Meyer K; Molinari M; Geller D; Tohme S Am Surg; 2021 Nov; 87(11):1766-1774. PubMed ID: 34766506 [TBL] [Abstract][Full Text] [Related]
19. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment. Parikh AR; Chee BH; Tsai J; Rich TA; Price KS; Patel SA; Zhang L; Ibrahim F; Esquivel M; Van Seventer EE; Jarnagin JX; Raymond VM; Corvera CU; Hirose K; Nakakura EK; Corcoran RB; Van Loon K; Atreya CE Clin Cancer Res; 2024 Jul; 30(14):2964-2973. PubMed ID: 38695832 [TBL] [Abstract][Full Text] [Related]
20. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE; J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]